Inspire Medical Systems, Inc.
75.17-2.00 (-2.59%)
Oct 29, 4:00:02 PM EDT · NYSE · INSP · USD
Key Stats
Market Cap
2.22BP/E (TTM)
43.20Basic EPS (TTM)
1.74Dividend Yield
0%Recent Filings
8-K
CFO Buchholz to step down
Inspire Medical Systems' CFO Richard J. Buchholz steps down August 22, 2025, to pursue other opportunities, with no disputes involved. He'll serve as principal financial officer until December 31, 2025, or a successor's start, then advise through February 28, 2026, receiving $358,500 severance and COBRA coverage. The company launched a search for a replacement. Inspire reaffirms 2025 guidance: revenue $900-910 million, gross margin 84-86%, diluted EPS $0.40-0.50. Leadership transitions test continuity amid growth.
8-K
Board approves $200M buyback
Inspire Medical Systems announced on August 11, 2025, that its board authorized a $200 million share repurchase program, set to expire August 7, 2027, or upon depletion of funds. This move signals confidence in undervalued stock amid the full U.S. launch of its next-generation Inspire V neurostimulation system for obstructive sleep apnea. The company balances heavy investments in marketing and expansion with capital returns to shareholders. Yet, repurchases hinge on market conditions and liquidity.
10-Q
Q2 FY2025 results
Inspire Medical Systems posted Q2 revenue of $217.1M, up 10.8% y/y from $195.9M but down from Q1's $201.3M (derived), as U.S. sales climbed 10.3% y/y to $207.2M amid deeper market penetration, though tempered by ENT surgeon shortages and delays for the new Inspire V rollout. Gross margin dipped to 84.0% from 84.8% y/y, pressured by a $2.1M excess inventory charge on Inspire IV parts, while operating loss widened to $3.3M from $5.1M profit, driven by 20.8% higher SG&A from headcount growth and marketing. Net loss hit $3.6M or $(0.12) diluted EPS, matching basic shares of 29.5M with no dilution; YTD net loss was slim at $0.6M. Cash and equivalents stood at $106.9M with $303.8M in investments, but share repurchases drained $75.0M, leaving no program balance. Strategic investment impairment of $4.0M stung other income. Yet competition from rivals like Nyxoah lingers.
8-K
Inspire Q2 revenue up 11%, guidance cut
Inspire Medical Systems reported Q2 2025 revenue of $217.1 million, up 11% year-over-year, with a solid 84.0% gross margin but swung to a $3.6 million net loss from prior profit, driven by higher operating expenses and a $4.0 million investment impairment. The company launched its FDA-cleared Inspire V neurostimulation system in the U.S., touting simplified procedures and strong early feedback, yet the rollout lags expectations, delaying full transition. It slashed full-year revenue guidance to $900-910 million from $940-955 million, while maintaining 84-86% gross margins. Executive VP Randall Ban plans retirement on January 30, 2026. Transition delays pose near-term risks.
8-K
Inspire V device launch
Inspire Medical Systems unveiled its Inspire V device at the Wells Fargo 2025 MedTech Innovation Spotlight on June 13, 2025, featuring accelerometer-based respiration sensing that eliminates a lead, cuts implant time by 20%, and boosts therapy performance while reducing revisions. This closed-loop system targets the vulnerable inhalation phase to prevent airway collapse in obstructive sleep apnea patients, with full launch set for May 2025. Peer-reviewed data from SLEEP 2024 and 2025 validate its efficacy, especially in supine positions. Inspire V simplifies procedures yet demands precise timing.
IINN
Inspira Technologies Oxy B.H.N.
1.00-0.05
INGN
Inogen, Inc
8.41-0.12
IRME
IR-Med Inc.
0.03+0.00
NMTC
NeuroOne Medical Technologies C
0.79-0.03
NSPR
InspireMD Inc.
2.27+0.04
NXL
Nexalin Technology, Inc.
1.55+0.07
NYXH
Nyxoah SA
5.09+0.08
RMD
ResMed Inc.
253.62-2.95
RMSL
RemSleep Holdings, Inc.
0.00+0.00
VVOS
Vivos Therapeutics, Inc.
2.67+0.07